The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Abstract
Glucagon-like peptide-1 (GLP-1), an incretin hormone, is released from intestinal L-cells in response to nutrients. GLP-1 lowers blood glucose levels by stimulating insulin secretion from pancreatic beta-cells in a glucose-dependent manner. In addition, GLP-1 slows gastric emptying, suppresses appetite, reduces plasma glucagon, and stimulates glucose disposal, which are beneficial for glucose homeostasis. Therefore, incretin-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase IV, an enzyme which inactivates GLP-1, have been developed for treatment of diabetes. This review outlines our knowledge of the actions of GLP-1 on insulin secretion and biosynthesis, beta-cell proliferation and regeneration, and protection against beta-cell damage, as well as the involvement of recently discovered signaling pathways of GLP-1 action, mainly focusing on pancreatic beta-cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors are employed either as an add-on drug therapy when metformin (a biguanide), or sulfonylurea is inadequate or as monotherapy in individuals who should not be taking those medications or who are intolerant to them (70).”
In the citing paper
“It stimulates insulin release and secretion in hyperglycemic states, inhibits glucagon release in hyperglycemic or euglycemic states, slows gastric emptying, and reduces food intake.(6, 7)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [6]
In the citing paper
“The hormone binds to GLP-1 receptors expressed in tissues such as the pancreatic beta cells, gastric mucosa, kidney, heart, and hypothalamus.(6, 7)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [6]
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The mechanism of pancreatic secretion
Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,274
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995 · cited 2×
“[12] Jang HJ, Kokrashvili Z, Theodorakis MJ, et al.”
BackgroundPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Cited by
Sorted by citations
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
“GLP-1 has many beneficial effects on the control of blood glucose levels including stimulation of insulin secretion and inhibition of glucagon secretion, expansion of the beta-cell mass by stimulating beta-cell proliferation and differentiation and inhibiting beta-cell apoptosis, delay of gastric emptying, and reducti…”
BackgroundSelf-citationModulatory Effects of Probiotics During Pathogenic Infections With Emphasis on Immune Regulation
Raheem, A., Liang, L., Zhang, G., & Cui, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616713 · Cited by 323
Dahlén, A. D., Dashi, G., Maslov, I. O., Attwood, M. M., Jonsson, J., Trukhan, V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807548 · Cited by 308
Wang, Y., Dilidaxi, D., Wu, Y., Sailike, J., Sun, X., & Nabi, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109914 · Cited by 281
Mechanisms of the anorexia of aging—a review
Wysokiński, A., Sobów, T., Kłoszewska, I., & Kostka, T. (2015) · AGE · doi:10.1007/s11357-015-9821-x · Cited by 245
Semaglutide for the treatment of obesity
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.008 · Cited by 227
TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Alhawiti, N. M., Mahri, S. A., Aziz, M. A., Malik, S. S., & Mohammad, S. (2017) · Current Drug Targets · doi:10.2174/1389450118666170130145514 · Cited by 226
Makrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 233
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
Self-citationRegulation of Bim in Health and Disease
Sionov, R. V., Vlahopoulos, S., & Granot, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.5492 · Cited by 233
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173
Current and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 159
Badawi, G. A., Fattah, M. A. A. E., Zaki, H. F., & Sayed, M. I. E. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0331-6 · Cited by 125
Glucagon-Like Peptide 1 Increases β-Cell Regeneration by Promoting α- to β-Cell Transdifferentiation
Lee, Y.-S., Lee, C., Choung, J.-S., Jung, H.-S., & Jun, H.-S. (2018) · Diabetes · doi:10.2337/db18-0155 · Cited by 114
Self-citationMa, Z., Dai, J., Zhang, W., Yuan, Y., Liao, H., Zhang, N., Bian, Z., & Tang, Q. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13449 · Cited by 109
Seo, E., Lim, J. S., Jun, J.-B., Choi, W., Hong, I., & Jun, H. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1145-4 · Cited by 109
Self-citationScheen, A. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.978289 · Cited by 106
Li, J., Fang, B., Pang, G., Zhang, M., & Ren, F. (2019) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2019.05.018 · Cited by 107
B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
Alam, M., Ali, S., Mohammad, T., Hasan, G. M., Yadav, D. K., & Hassan, M. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910442 · Cited by 97
Mesinovic, J., Fyfe, J. J., Talevski, J., Wheeler, M. J., Leung, G. K. W., George, E. S., Hunegnaw, M. T., Glavas, C., Jansons, P., Daly, R. M., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0112 · Cited by 98
Gupta, P., Bala, M., Gupta, S. K., Dua, A., Dabur, R., Injeti, E. R., & Mittal, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.029 · Cited by 92
Lee, S., & Lee, D. Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 81
COUP-TFII in Health and Disease
Polvani, S., Pepe, S., Milani, S., & Galli, A. (2019) · Cells · doi:10.3390/cells9010101 · Cited by 76
Bedinger, D., & Adams, S. H. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.08.013 · Cited by 85
Metabolic and cardiovascular benefits of GLP‑1 agonists, besides the hypoglycemic effect (Review)
Iorga, R., Bacalbașa, N., Carşote, M., Bratu, O. G., Stănescu, A. M. A., BUNGAU, S. G., Pantiș, C., & Diaconu, C. C. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8714 · Cited by 79
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
Thompson, A., & Kanamarlapudi, V. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.015 · Cited by 74
Recent advances of dicyano-based materials in biology and medicine
Zhang, W., Huo, F., & Yin, C. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb02205d · Cited by 71
Spotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 89
Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
DPP-4 inhibitors: focus on safety
Tella, S. H., & Rendell, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.977863 · Cited by 63
The role of selenium in insulin resistance
Fontenelle, L. C., Feitosa, M. M., Morais, J. B. S., Severo, J. S., de Freitas, T. E. C., Beserra, J. B., Henriques, G. S., & Marreiro, D. D. N. (2018) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902018000100139 · Cited by 62
Tegegne, B. A., Adugna, A., Yenet, A., Yihunie Belay, W., Yibeltal, Y., Dagne, A., Hibstu Teffera, Z., Amare, G. A., Abebaw, D., Tewabe, H., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1440456 · Cited by 61
Sandberg, J. C., Björck, I., & Nilsson, A. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151985 · Cited by 64
Liu, T., Ning, J., Wang, B., Dong, B., Li, S., Tian, X., Yu, Z., Peng, Y., Wang, C., Zhao, X., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04957 · Cited by 57
Peralta, F. G., Abreu, C., Rodríguez, S. G., Barranco, R. J., & Umpierrez, G. E. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0488-z · Cited by 63
Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice
Xu, Q., Zhang, X., Li, T., & Shao, S. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00574-6 · Cited by 61
Li, Z., Ni, C.-L., Yao, Z., Chen, L.-M., & Niu, W.-Y. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.008 · Cited by 56
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
“In addition, GLP-1 also increases proinsulin gene expression and insulin biosynthesis, through a mechanism involving cAMP/PKAdependent and -independent signaling pathways [62,63].”
BackgroundInfluentialMichael, E. S., Covic, L., & Kuliopulos, A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005464 · Cited by 56
Yang, F., Li, J., Pang, G., Ren, F., & Fang, B. (2019) · Molecules · doi:10.3390/molecules24102003 · Cited by 58
The Role and Mechanisms of Selenium Supplementation on Fatty Liver-Associated Disorder
Xu, L., Lu, Y., Wang, N., & Feng, Y. (2022) · Antioxidants · doi:10.3390/antiox11050922 · Cited by 53
Yuan, T., Yin, Z., Yan, Z., Hao, Q., Zeng, J., Li, L., & Zhao, J. (2020) · Fitoterapia · doi:10.1016/j.fitote.2020.104665 · Cited by 51
Cimino, G., Vaduganathan, M., Lombardi, C., Pagnesi, M., Vizzardi, E., Tomasoni, D., Adamo, M., Metra, M., & Inciardi, R. M. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14560 · Cited by 62
Wei, T., Cui, X., Jiang, Y., Wang, K., Wang, D., Li, F., Lin, X., Gu, L., Yang, K., Yang, J., et al. (2023) · Diabetes · doi:10.2337/db22-0784 · Cited by 50
Musaimi, O. A. (2024) · Biomolecules · doi:10.3390/biom14030264 · Cited by 51
Zhan, J., Wang, Y., Wang, Y., Tang, Z.-Y., Tan, P., Huang, W., & Liu, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.086 · Cited by 51
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
Imbroane, M. R., LeMoine, F., & Nau, C. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.01.019 · Cited by 49
Kassem, D., Kamal, M. M., El-Kholy, A., & El-Mesallamy, H. (2016) · Stem cell research & therapeutics · doi:10.1186/s13287-016-0374-4 · Cited by 43
Liu, W., Son, D. O., Lau, H., Zhou, Y., Prud’homme, G. J., Jin, T., & Wang, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00362 · Cited by 50
Jiang, W., Peng, Y., & Yang, K. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6603 · Cited by 50
GLP-1 Receptor: A New Target for Sepsis
Yang, F., Zeng, F., Luo, X., Lei, Y., Li, J., Lu, S., Huang, X., Lan, Y., & Liu, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706908 · Cited by 48
Compare And Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs)
Latif, W. A., Lambrinos, K. J., & Rodríguez, R. (2021) · StatPearls · Cited by 47
Borowiec, A. M., Właszczuk, A., Olakowska, E., & Lewin‐Kowalik, J. (2022) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2187 · Cited by 46
Investigational insulin secretagogues for type 2 diabetes
Scheen, A. J. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1152260 · Cited by 49
Wu, S., Gao, L., Cipriani, A., Huang, Y., Yang, Z., Yang, J., Yu, S., Zhang, Y., Chai, S., Zhang, Z., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13613 · Cited by 47
Li, L., Xie, J., Zhang, Z., Xia, B., Li, Y., Lin, Y., Li, M., Wu, P., & Lin, L. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128873 · Cited by 44
Anti-incretin, Anti-proliferative Action of Dopamine on β-Cells
Maffei, A., Segal, A. M., Álvarez-Pérez, J. C., Garcı́a-Ocaña, A., & Harris, P. E. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1273 · Cited by 50
Hayashi, H., Yamada, R., Das, S., Sato, T., Takahashi, A., Hiratsuka, M., & Hirasawa, N. (2014) · Metabolism · doi:10.1016/j.metabol.2014.02.012 · Cited by 46
Peptides from frog skin with potential for development into agents for Type 2 diabetes therapy
Conlon, J. M., Mechkarska, M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2017) · Peptides · doi:10.1016/j.peptides.2017.09.001 · Cited by 47
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Tilinca, M. C., Tiucă, R. A., Burlacu, A., & Varga, A. (2021) · Medicina · doi:10.3390/medicina57070669 · Cited by 45
Zummo, F. P., Krishnanda, S. I., Georgiou, M., O'Harte, F. P. M., Parthsarathy, V., Cullen, K. S., Honkanen‐Scott, M., Shaw, J., Lovat, P. E., & Arden, C. (2021) · Autophagy · doi:10.1080/15548627.2021.1956123 · Cited by 43
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
A new hypoglycemic mechanism of catalpol revealed by enhancing MyoD/MyoG-mediated myogenesis
Xu, D., Wang, L., Jiang, Z., Zhao, G., Hassan, H. M., Sun, L., Fan, S., Zhou, Z., Zhang, L., & Wang, T. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.08.028 · Cited by 42
Tanaka, M., Matsuo, Y., Yamakage, H., Masuda, S., Terada, Y., Muranaka, K., Wada, H., Hasegawa, K., Shimatsu, A., & Satoh‐Asahara, N. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.009 · Cited by 41
Hamza, A. A., Fikry, E. M., Hassan, W. A., & Amin, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-28029-1 · Cited by 41
Oprea, A. D., Umpierrez, G. E., Sweitzer, B., & Hepner, D. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005204 · Cited by 42
Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway
Zhan, J., Tan, P., Wang, Y., Wang, Y., He, J., Tang, Z.-Y., Huang, W., & Liu, Y. (2014) · Cardiovascular Diabetology · doi:10.1186/preaccept-6481332511368690 · Cited by 39
Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
Yang, F., Luo, X., Li, J., Yu, L., Zeng, F., Huang, X., Lan, Y., & Liu, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113236 · Cited by 43
Khanal, S., Ghimire, P., & Dhamoon, A. S. (2019) · Biomedicines · doi:10.3390/biomedicines7010010 · Cited by 37
Ayoub, M., Faris, C., Juranovic, T., Chela, H. K., & Daglilar, E. S. (2024) · Cancers · doi:10.3390/cancers16091625 · Cited by 38
Capuccio, S., Scilletta, S., Rocca, F. L., Miano, N., Marco, M. D., Bosco, G., Barbagallo, F. D. G., Scicali, R., Piro, S., & Pino, A. D. (2024) · Biomolecules · doi:10.3390/biom14060687 · Cited by 41
Beneficial effects of psyllium on the prevention and treatment of cardiometabolic diseases
Chen, C., Shang, C., Xin, L., Xiang, M., Wang, Y., Shen, Z., Jiao, L., Ding, F., & Cui, X. (2022) · Food & Function · doi:10.1039/d2fo00560c · Cited by 36
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Wojtara, M., Mazumder, A., Syeda, Y., & Mozgała, N. (2023) · Advances in Medicine · doi:10.1155/2023/9946924 · Cited by 36
Li, J., Su, L., Gong, Y., Ding, M., Hong, S., Yu, S., & Xiao, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173576 · Cited by 35
Ravarotto, V., Bertoldi, G., Innico, G., Gobbi, L., & Calò, L. A. (2021) · Antioxidants · doi:10.3390/antiox10071041 · Cited by 35
Long-Wavelength Ratiometric Fluorescent Probe for the Early Diagnosis of Diabetes
Wang, J., Zhang, L., Qu, Y., Yang, Y., Cao, T., Cao, Y., Iqbal, A., Qin, W., & Liu, Y. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c01491 · Cited by 35
Leibowitz, G., Cahn, A., Bhatt, D. L., Hirshberg, B., Mosenzon, O., Wei, C., Jermendy, G., Sheu, W. H., Sendon, J. L., Im, K., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12445 · Cited by 34
Wu, H., Mao, X.-F., Fan, H. J., & Wang, Y. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107102 · Cited by 34
Yin, W., Jiang, Y., Xu, S., Wang, Z., Peng, L., Fang, Q., Deng, T., Zhao, W., Zhang, W., & Lou, J. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12956 · Cited by 32
Diabetes and Cardiovascular Risk in Renal Transplant Patients
Rysz, J., Franczyk, B., Radek, M., Ciałkowska-Rysz, A. D., & Gluba-Brzózka, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073422 · Cited by 36
Khanna, V., Malin, S. K., Bena, J., Abood, B., Pothier, C. E., Bhatt, D. L., Nissen, S. E., Watanabe, R. M., Brethauer, S. A., Schauer, P. R., et al. (2015) · Obesity · doi:10.1002/oby.21021 · Cited by 33
Perspectives on evaluating health effects of starch: Beyond postprandial glycemic response
Kong, H., Yu, L., Li, C., Ban, X., Gu, Z., Liu, L., & Li, Z. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119621 · Cited by 34
Big peptide drugs in a small molecule world
Otvos, L. J., & Wade, J. D. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1302169 · Cited by 33
Liraglutide prevents β-cell apoptosis via inactivation of NOX2 and its related signaling pathway
Ding, M., Fang, Q., Cui, Y., Shen, Q.-L., Liu, Q., Wang, P., Yu, D. M., & Li, C. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.12.013 · Cited by 33
Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity.
Nolen-Doerr, E., Stockman, M.-C., & Rizo, I. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00350-4 · Cited by 32
Sarker, D. K., Ray, P., Dutta, A. K., Rouf, R., & Uddin, S. J. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4440 · Cited by 32
Nakhla, M., Nair, A. V., Balani, P., Ujjawal, A., Kumar, P. A., Dasari, M., Yukselen, Z., Bansal, K., Ganatra, S., & Dani, S. S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07613-w · Cited by 32
Skytte, M. J., Samkani, A., Astrup, A. V., Frystyk, J., Rehfeld, J. F., Holst, J. J., Madsbad, S., Burling, K., Fenger, M., Thomsen, M. N., et al. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00165.2020 · Cited by 43
Obesity in children and adolescents: Overview of the diagnosis and management
Tung, J. Y., Poon, G. W.-K., Du, J., & Wong, K. K. (2023) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.58 · Cited by 36
Exendin-4 increases oxygen consumption and thermogenic gene expression in muscle cells
Choung, J.-S., Lee, Y.-S., & Jun, H.-S. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0078 · Cited by 31
Self-citationCurrent Perspectives on Management of Type 2 Diabetes in Youth
Singhal, S., & Kumar, S. (2021) · Children · doi:10.3390/children8010037 · Cited by 32
Musale, V., Casciaro, B., Mangoni, M. L., Abdel‐Wahab, Y. H. A., Flatt, P. R., & Conlon, J. M. (2018) · Journal of Peptide Science · doi:10.1002/psc.3065 · Cited by 30
Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists
Kelly, C. A., & Sipos, J. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae722 · Cited by 30
Pinheiro, M. M., Pinheiro, F. M. M., & Trabachin, M. L. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.02.003 · Cited by 29
Ren, L., Cui, Q., Liu, W., Wang, L., Liao, Y., Feng, Y., Sun, W., Yang, Y., Zhang, Z., Jin, T., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00930 · Cited by 29
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
Correale, M., Lamacchia, O., Ciccarelli, M., Dattilo, G., Tricarico, L., & Brunetti, N. D. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10157-y · Cited by 29
Tilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 30
Son, D. O., Liu, W., Li, X., Prud’homme, G. J., & Wang, Q. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12881 · Cited by 28
Metadata
- Authors
- Lee, Y.-S., & Jun, H.-S.
- Affiliations
- Gachon University (KR)
- Corresponding author
- Jun, Hee-Sook
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 63
- Issue
- 1
- Pages
- 9-19
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2063865446
- Cited by
- 315
- References
- 101
- Citations by year
- 2026: 15 · 2025: 34 · 2024: 34 · 2023: 26 · 2022: 28 · 2021: 35 · 2020: 26 · 2019: 21 · 2018: 27 · 2017: 16 · 2016: 17 · 2015: 19 · 2014: 16
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, incretins, pancreatic beta cells, insulin secretion, insulin biosynthesis, beta-cell proliferation, beta cell regeneration, beta cell destruction, glucose homeostasis, diabetes treatment, GLP-1 receptor agonists, DPP-4 inhibitors
- MeSH terms
- Insulin Secretion, Animals, Cell Differentiation, Cell Survival, Humans, Hypoglycemic Agents, Insulin, Signal Transduction, Cell Proliferation, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
